Salmaan Keshavjee, MD, Ph.D, MA, Sc.M, is the Director of the Program in Infectious Disease and Social Change at the Department of Global Health and Social Medicine (DGHSM) at Harvard Medical School. Trained as a physician and social anthropologist, Dr. Keshavjee is an Assistant Professor of Medicine and Social Medicine at Harvard Medical School and in the Division of Global Health Equity at Brigham and Women’s Hospital. He is also an attending in Internal Medicine at Brigham and Women’s Hospital. Dr. Keshavjee completed his thesis work in Harvard’s Department of Anthropology and Center for Middle Eastern Studies on health policies in post-Soviet Tajikistan. Dr. Keshavjee’s clinical research has focused on the implementation of drug-resistant tuberculosis treatment projects run by Partners In Health, and associated treatment outcomes. He has worked extensively with PIH’s drug-resistant tuberculosis program in Russia since 2000. From 2006 to 2008, he was Deputy Country Director for the PIH Lesotho Initiative, launching one of the first community-based treatment programs for multi-drug resistant tuberculosis/HIV co-infection in sub-Saharan Africa. Since 2007 he has led PIH’s Russia research initiative, coordinating a multi-disciplinary team studying treatment outcomes in drug-resistant tuberculosis. This work is informing efforts to treat drug-resistant tuberculosis in the region, including Central Asia, and has resulted in several manuscripts of global clinical and policy significance. Starting in 2005, Dr. Keshavjee has represented PIH/Harvard on the Green Light Committee (GLC) for multi-drug resistant tuberculosis, the principal global mechanism for MDR-TB treatment expansion, housed at the Stop TB Partnership and the World Health Organization. From 2007 until September, 2010, he served as the Committee’s Chair. Through his roles at Harvard, PIH and the GLC, he has advised numerous national programs on the clinical and programmatic management of MDR-TB.